Breast cancer is one of the top three malignancies worldwide. While radiotherapy, hormone replacement therapys, and chemotherapy are treatments, chemotherapy causes adverse effects that hinder daily life activities.
Objectives
To assess the prevalence, severity, and association of symptomatic toxicities in female breast cancer patients affecting various organ systems post systemic chemotherapy (adjuvant and neoadjuvant), and their impact on daily activities. Additionally, to determine the severity of adverse effects in specific age groups and their association with family history and disease stage.
Methodology
An observational study was conducted on 253 female breast cancer patients receiving chemotherapy at NORI Cancer Hospital from May to October 2023. Data collection tools included the NCI-PRO-CTCAE standardized questionnaire and patient medical records. Analysis was performed using descriptive statistics, T-tests, and Chi-square tests.
Results
Among the 253 patients, 41.4% were aged 41–50. Significant weight changes (p = 0.034) were observed with more than three chemotherapy cycles. Notable associations included increased chemotherapy cycles with gastrointestinal (mouth/throat sores p = 0.031, vomiting p = 0.021), respiratory (cough p = 0.04), cardiovascular (arm/leg swelling p = 0.007, palpitations p = 0.052), integumentary (hair loss p = 0.000, skin dryness p = 0.054), and musculoskeletal (fatigue p = 0.002) adverse effects. Positive family history and the 18–30 age group also showed significant associations with adverse effect severity. Disease stage significantly influenced the nervous system (stage 2 p = 0.007, stage 3 p = 0.01).
Conclusion
The severity of adverse effects varies among age groups, depending on disease stage, genetics, and treatment duration. These patient-reported outcomes highlight the need for better management strategies considering prognostic factors and treatment adverse effects.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
2.
VervoortMMDraismaGFracheboudJ, et al.Trends in the usage of adjuvant systemic therapy for breast cancer in The Netherlands and its effect on mortality. Br J Cancer2004; 91: 242–247.
WilkinsonLGathaniT. Understanding breast cancer as a global health concern. Br J Radiol2021; 95. DOI: 10.1259/bjr.20211033.
5.
SiegelRDeSantisCVirgoK, et al.Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin2012; 62: 220–241.
6.
PartridgeAHBursteinHJWinerEP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. JNCI Monogr2001; 2001: 135–142.
7.
InvernizziMKimJFuscoN. Editorial: Quality of life in breast cancer patients and survivors. Front Oncol2020; 10. DOI: 10.3389/fonc.2020.620574
8.
BardwellWAAncoli-IsraelS. Breast cancer and fatigue. Sleep Med Clin2008; 3: 61–71.
9.
CoatesAAbrahamSKayeSB, et al.On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol1983; 19: 203–208.
10.
MarstrandSDBuch-LarsenKAnderssonM, et al.Vibration perception threshold and heart rate variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer – a pilot study. Cancer Treat Res Commun2021; 28: 100426
11.
BattagliniEGoldsteinDGrimisonP, et al.Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes. J Natl Compr Cancer Network2021; 19: 821–828.
12.
ImanianMImanianMKarimyarM, Sleep quality and fatigue among breast cancer patients undergoing chemotherapy. Int J Hematol Oncol Stem Cell Res2019; 13: 196–200.
13.
HormoziMHashemiSMShahrakiS.Investigating relationship between pre- and post-chemotherapy cognitive performance with levels of depression and anxiety in breast cancer patients: a cross-sectional study. Asian Pac J Cancer Prev: APJCP2019; 20: 3831–3837.
14.
LeeJLimJParkJS, et al.The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat2018; 50: 1186–1193.
15.
VieiraRABillerGUemuraG, et al.Breast cancer screening in developing countries. Clinics2017; 72: 244–253.
16.
StoutNLBinkleyJMSchmitzKH, et al.A prospective surveillance model for rehabilitation for women with breast cancer. Cancer2012; 118: 2191–2200.
17.
JagsiRGriffithKAViciniFA, et al.Identifying patients whose symptoms are underrecognized during treatment with breast radiotherapy. JAMA Oncol2022; 8: 887–887.
18.
AhlesTASaykinAJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer2002; 3: S84–S90.
19.
KhalafHMohammedAShukurS, et al.Breast cancer: age incidence, hormone receptor status and family history in Najaf, Iraq. J Med Life2022; 15: 1318–1321.
20.
BarnesNLPBolandGPDavenportA, et al.Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg2005; 92: 429–434.
21.
BouwensCSHvan RensburgSJde KockL, et al.Influence of genetic factors on the development of breast cancer in the older woman. Curr Aging Sci2012; 5: 140–147.
22.
WatanabeTYagataHSaitoM, et al.A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS ONE2019; 14: e0208118.
23.
NielsenAWMKristensenMHOffersenBV, et al.Patient-reported outcomes in postmenopausal breast cancer survivors – comparisons with normative data. Acta Oncol (Madr)2020; 60: 78–86.
24.
LiuLSuoTShenY, et al.Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res2020. DOI: https://doi.org/10.1007/s11136-020-02558-7.
25.
NoldenAAJosephPVKoberKM, et al.Co-occurring gastrointestinal symptoms are associated with taste changes in oncology patients receiving chemotherapy. J Pain Symptom Manag2019; 58: 756–765.
26.
TaoJJVisvanathanKWolffAC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast2015; 24: S149–S153.
27.
MauriDGazouliIZarkavelisG, et al.Chemotherapy associated ovarian failure. Front Endocrinol (Lausanne)2020; 11. DOI: 10.3389/fendo.2020.572388.
MaassSWMCBoermanLMBrandenbargD, et al.Symptoms in long-term breast cancer survivors: a cross-sectional study in primary care. Breast2020; 54: 133–138.
30.
VardyJLLiewAWarbyA, et al.On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century?Support Care Cancer2022. DOI:https://doi.org/10.1007/s00520-022-06804-1.
31.
TsarasKPapathanasiouIVMitsiD, et al.Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. Asian Pac J Cancer Prev: APJCP2018; 19: 1661–1669.
32.
MontemurroFMitticaGCagnazzoC, et al.Self-evaluation of adjuvant chemotherapy-related adverse effects by patients with breast cancer. JAMA Oncol2016; 2: 445.
33.
AcharyaSPaiKBhatS, et al.Oral changes in patients undergoing chemotherapy for breast cancer. Indian J Dent Res2017; 28: 261.
34.
ThivatEThérondelSLapirotO, et al.Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer2010; 10: 648.
35.
DendaYNiikuraNSatoh-KuriwadaS, et al.Taste alterations in patients with breast cancer following chemotherapy: a cohort study. Breast Cancer2020. DOI:https://doi.org/10.1007/s12282-020-01089-w.
36.
de VriesYCvan den BergMMGAde VriesJHM, et al.Differences in dietary intake during chemotherapy in breast cancer patients compared to women without cancer. Supportive Care in Cancer2017; 25: 2581–2591.
37.
VanceVCampbellSMccargarL, et al.The voice of experience: diet and weight change in women with breast cancer associate with psychosocial and treatment-related challenges. Can J Diet Pract Res2017; 78: 74–80.
38.
RashidNKohHABacaHC, et al.Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm2015; 21: 863–871.
CoughlinSS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat2019; 177: 537–548.
41.
GiacaloneAAlessandriaPRubertiE. The physiotherapy intervention for shoulder pain in patients treated for breast cancer: systematic review. Cureus2019; 11. DOI: 10.7759/cureus.6416.
42.
StacheNBohnSSperlichK, et al.Taxane-induced neuropathy and its ocular effects – a longitudinal follow-up study in breast cancer patients. Cancers202315: 2444.
43.
LiawYYLoongFSTanS, et al.A retrospective study on breast cancer presentation, risk factors, and protective factors in patients with a positive family history of breast cancer. Breast J2020; 26: 469–473.
44.
YipCHbt Mohd TaibNALauPC. Does a positive family history influence the presentation of breast cancer?Asian Pac J Cancer Prev2008; 9: 63–65.
45.
EcclesDGertySSimmondsP, et al.Prospective study of outcomes in sporadic versus hereditary breast cancer (POSH): study protocol. BMC Cancer2007; 7. DOI: 10.1186/1471-2407-7-160.
46.
SoroushAFarshchianNKomasiS, et al.The role of oral contraceptive pills on increased risk of breast cancer in Iranian populations: a meta-analysis. J Cancer Prevent2016; 21: 294–301.
47.
RaiRMalikMValiyaveettilD, et al.Assessment of late treatment-related symptoms using patient-reported outcomes and various factors affecting return to work in survivors of breast cancer. Ecancermedicalscience2023; 17. DOI: https://doi.org/10.3332/ecancer.2023.1533.
48.
AdesoyeTLiaoKPetersonSK, et al.Patient-reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment. Cancer Med2023; 12: 17740–17752.
49.
TasoC-JLinH-SLinW-L, et al.The effect of yoga exercise on improving depression, anxiety, and fatigue in women with breast cancer. J Nurs Res2014; 22: 155–164.
